Latest Articles
Woman files lawsuit after alleged cancer misdiagnosis leads to unnecessary hysterectomy - WTHI-TV
Woman files lawsuit after alleged cancer misdiagnosis leads to unnecessary hysterectomy WTHI-TV
Published: Aug. 4, 2026, 9:11 p.m.
'Medical misogyny': thousands of women face losing life-changing pain drug - The Advocate | Burnie, TAS
'Medical misogyny': thousands of women face losing life-changing pain drug The Advocate | Burnie, TAS
Published: Aug. 4, 2026, 6:31 p.m.
Laura Mbatha shares update on Natalie Githinji’s condition after hospital admission - K24 Digital
Laura Mbatha shares update on Natalie Githinji’s condition after hospital admission K24 Digital
Published: Aug. 4, 2026, 4:09 a.m.
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com - Investing.com UK
H.C. Wainwright cuts Karyopharm stock rating on trial miss By Investing.com Investing.com UK
Published: Aug. 1, 2026, 6:38 a.m.
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial - The Clinical Trial Vanguard
Karyopharm’s selinexor misses primary endpoint in Phase 3 endometrial cancer trial The Clinical Trial Vanguard
Published: Aug. 1, 2026, 6:33 a.m.
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer - Targeted Oncology
Selinexor Maintenance Misses Mark in TP53 Wild-Type Endometrial Cancer Targeted Oncology
Published: July 31, 2026, 8:06 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - OncLive
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer OncLive
Published: July 31, 2026, 5:22 p.m.
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - onclive.com
Selinexor Maintenance Misses PFS End Point in TP53 Wild-Type Endometrial Cancer onclive.com
Published: July 31, 2026, 5:22 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - CancerNetwork
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer CancerNetwork
Published: July 31, 2026, 2:37 p.m.
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer - cancernetwork.com
Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer cancernetwork.com
Published: July 31, 2026, 2:37 p.m.
Link copied to clipboard!